Clinical Trial Goal
To find out:
- The highest dose of ATG-031 that's safe to give
- If ATG-031 is safe and works well to treat B-NHL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have B-cell NHL that has relapsed or is refractory. Some examples include:
- Burkitt lymphoma
- Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL)
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Lymphoblastic lymphoma
- Mantle cell lymphoma (MCL)
- Marginal zone lymphoma (MZL)
- Primary Mediastinal large B-cell lymphoma (PMBCL)
- Waldenström's macroglobulinemia
- Do not have untreated lymphoma in your brain or spinal cord
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
ATG-031 is a monoclonal antibody that targets CD24 in certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- ATG-031 – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to about 1 year.
The Food and Drug Administration (FDA) has not yet approved ATG-031.
Locations
University of California San Francisco (UCSF)RECRUITING
San Francisco, California
Bridget Keenan, PhD
Regents of the University of ColoradoRECRUITING
Aurora, Colorado
Alexis Leal, MD
Yale UniversityRECRUITING
New Haven, Connecticut
Joseph Kim, MD
University of Texas M.D. Anderson Cancer CenterRECRUITING
Houston, Texas
Siqing Fu, MD
Sponsors
lead: Antengene Biologics Limited
